The methylation level of SLC22A3 was significantly increased in MDS and AML patients compared with controls (P < 0.001 and < 0.001), as well as in AML compared with MDS (P < 0.001; Fig. 2A). Here, SLC22A3 is linked to myelodysplastic syndrome.